Jyoti Malhotra, MD, MPH
Enriched profileDirector of Thoracic Medical Oncology, City of Hope Orange County (Lennar Foundation Cancer Center); Associate Professor, Department of Medical Oncology & Therapeutics Research · City of Hope National Medical Center
Jyoti Malhotra is Director of Thoracic Medical Oncology, City of Hope Orange County (Lennar Foundation Cancer Center); Associate Professor, Department of Medical Oncology & Therapeutics Research at City of Hope National Medical Center. OpenAlex indexes 276 publications with 11,751 citations (h-index 44); ClinicalTrials.gov lists 7 registered studies with this person as an investigator.
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Jyoti Malhotra, MD, MPH, is Director of Thoracic Medical Oncology, City of Hope Orange County (Lennar Foundation Cancer Center) at City of Hope National Medical Center (Orange County / Lennar Foundation Cancer Center). The public record shows 276 publications with 11,751 citations (h-index 44), centered on Breast Cancer, Melanoma, Prostate Cancer. It also documents an investigator role on 7 registered clinical trials, industry payments reported by 21 companies.
- Most recent indexed publication: 2026 · Cancer research communications
- Top research focus: Breast Cancer
- 7 registered trials on ClinicalTrials.gov
- Open Payments reporting from 21 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 13 in PubMed.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 7 registered studies on ClinicalTrials.gov. The most recent:
- Carfilzomib in Combination With Sotorasib for the Treatment of Patients With KRAS G12C Mutated Advanced or Metastatic Non-small Cell Lung Cancer
Sponsor: City of Hope Medical Center
Industry payments
Updated 27 Aug 2026
21 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- E.R. Squibb & Sons, L.L.C.Program year202518 payments$18,661openpaymentsdata.cms.gov ↗
- AstraZeneca Pharmaceuticals LPProgram year202513 payments$10,998openpaymentsdata.cms.gov ↗
- Janssen Biotech, Inc.Program year20255 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
52.5%Kinase inhibitor43.7%Tagrisso78%Alecensa16%Retevmo6%Part D<11 patientsOther antineoplastic agents5.7%Lumakras100%Part D<11 patientsMetabolism & gastrointestinal
18.4%Serotonin-3 Receptor Antagonist11.2%Ondansetron Hcl100%Part D≥19 patientsCorticosteroid4.5%Prednisone100%Part D≥14 patientsSensory organs
9.1%Corticosteroid9.1%Dexamethasone100%Part D≥22 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors.
Cancer research communications
Clinical Trial2026 - Treating EGFR-mutant nonsmall cell lung cancer is no longer a one-size-fits-all approach.
CA: a cancer journal for clinicians
Editorial2025
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/jyoti-malhotra-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - X / Twitter
x.com/jyotimalhotramd
Mentions by others
where others cite or feature them- Facebook
m.facebook.com/cityofhope/photos/jyoti-malhotra-md-mph-director-of-thoracic-medical-oncology-for-city-of-hope-ora/1060125872819490
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →m.facebook.com ↗ - Facebook
facebook.com/cityofhope/posts/jyoti-malhotra-md-mph-director-of-thoracic-medical-oncology-for-city-of-hope-ora/1060125902819487
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →facebook.com ↗ - Instagram
instagram.com/p/DB-OxFbNbj8
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →instagram.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →pub.orcid.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →pub.orcid.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →pub.orcid.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →pub.orcid.org ↗
- Board Certified
American Board of Internal Medicine (ABIM) - Medical Oncology, Hematology, and Internal Medicine
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →health.usnews.com ↗
Editorial & leadership roles
journal and society appointments- Member
National Comprehensive Cancer Network (NCCN) guideline panel for small cell lung cancer
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →cityofhope.org ↗ - Active member
SWOG (Southwest Oncology Group) cooperative group thoracic committee
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →cityofhope.org ↗ - Member
IASLC (International Association for the Study of Lung Cancer) Global Multidisciplinary Practice Standards Committee
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →cityofhope.org ↗
Secondary affiliations
appointments beyond the home institution- Formerly: Rutgers Cancer Institute of New Jersey
attending physician / acting director thoracic oncology (2015-2022); Assistant Professor, Robert Wood Johnson Medical School (2015-2021) -- prior institution, not current
2021provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →cinj.org ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cityofhope.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →curetoday.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Sumanta Pal, MD
City of Hope National Medical Center
Joanne Mortimer, MD
City of Hope National Medical Center
Tanya Dorff, MD
City of Hope National Medical Center
Alex Herrera, MD
City of Hope National Medical Center